| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Amarin Corp (NASDAQ:AMRN) reported quarterly earnings of $0.19 per share. This is a 119 percent increase over losses of $(1.00)...
 
																	
 
																	
 
																	 
																	HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focusing on addressing unmet...
 
																	DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company commi...
 
																	2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl as Class IIA Recommended Therapy in High...
 
																	 
																	Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congres...